The general public's knowledge of biotech has increased and improved exponentially following the pandemic. That is perhaps one of the positives we can take from Covid-19: Pfizer, Moderna, BionTech and AstraZeneca are all now household names.

Just as the public's knowledge has improved, so too have investors woken up to the opportunities and possibilities investing in biotechnology could bring. Before Covid-19 put a petri-dish around the...

Attachments

  • Original document
  • Permalink

Disclaimer

BB Biotech AG published this content on 13 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2021 13:11:09 UTC.